On January 4, 2024 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that management will participate in the 13th Annual LifeSci Partners Corporate Access Event, taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week (Press release, Kineta, JAN 4, 2024, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-the-13th-annual-lifesci-partners-corporate-access-event [SID1234638977]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to participating in the LifeSci Corporate Access Event and to hosting in-person meetings with investors, strategic partners, analysts and other stakeholders", said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. "2024 has the potential to be a substantial growth year as we continue to make significant progress on the clinical development of KVA12123, our novel VISTA immunotherapy."
During the event, the Kineta management team will host one-on-one meetings on January 8th and 9th, 2024 and will be available to present a corporate overview and provide an update on the VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors.
To schedule a meeting, please register at LifeSci Partners Corporate Access Event 2024.